在同时存在EML4-ALK融合基因和EGFR突变的肺腺癌中，吉非替尼有良好疗效。 - Suppr

Suppr

超能文献

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

作者信息

Kuo Yao-Wen, Wu Shang-Gin, Ho Chao-Chi, Shih Jin-Yuan

机构信息

Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.

出版信息

J Thorac Oncol. 2010 Dec;5(12):2039-40. doi: 10.1097/JTO.0b013e3181f43274.

DOI:10.1097/JTO.0b013e3181f43274

PMID:21102267

Abstract

摘要

相似文献

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

J Thorac Oncol. 2010 Dec;5(12):2039-40. doi: 10.1097/JTO.0b013e3181f43274.

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.

J Thorac Oncol. 2014 May;9(5):e37-9. doi: 10.1097/JTO.0000000000000097.

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.

J Clin Oncol. 2011 Jun 1;29(16):e468-9. doi: 10.1200/JCO.2010.33.5802. Epub 2011 Mar 21.

Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

Oncologist. 2008 Dec;13(12):1276-84. doi: 10.1634/theoncologist.2008-0093. Epub 2008 Dec 5.

A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib.

J Thorac Oncol. 2014 Jun;9(6):e47-8. doi: 10.1097/JTO.0000000000000186.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13.

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

Lung Cancer. 2011 Jan;71(1):65-9. doi: 10.1016/j.lungcan.2010.04.005.

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

J Clin Oncol. 2005 Jan 1;23(1):235-7. doi: 10.1200/JCO.2005.07.169.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5.

引用本文的文献

Case report: Concomitant mutation and rearrangement in non-small cell lung cancer.

Front Pharmacol. 2023 Aug 29;14:1167959. doi: 10.3389/fphar.2023.1167959. eCollection 2023.

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.

NPJ Precis Oncol. 2022 Nov 11;6(1):84. doi: 10.1038/s41698-022-00325-0.

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.

Thorac Cancer. 2022 Feb;13(4):637-642. doi: 10.1111/1759-7714.14291. Epub 2021 Dec 28.

Successful management of a lung cancer patient harbouring both mutation and fusion gene with disseminated intravascular coagulation.

Respir Med Case Rep. 2021 Mar 19;33:101393. doi: 10.1016/j.rmcr.2021.101393. eCollection 2021.

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors.

Front Oncol. 2021 Jan 15;10:544579. doi: 10.3389/fonc.2020.544579. eCollection 2020.

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.

Diagn Pathol. 2020 May 6;15(1):42. doi: 10.1186/s13000-020-00969-1.

Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.

J Glob Oncol. 2019 Sep;5:1-9. doi: 10.1200/JGO.19.00174.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.

Target Oncol. 2019 Apr;14(2):169-178. doi: 10.1007/s11523-019-00628-6.

Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib.

Lung India. 2018 Nov-Dec;35(6):527-529. doi: 10.4103/lungindia.lungindia_30_18.

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):686-691. doi: 10.3779/j.issn.1009-3419.2018.09.07.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验